Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

In this phase 1–2 trial, the TK inhibitor repotrectinib led to an objective response in 79% of patients with ROS1 fusion–positive NSCLC and no previous ROS1 TK inhibitor use. Median progression-free survival was nearly 3 years.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2024-01, Vol.390 (2), p.118-131
Hauptverfasser:	Drilon, Alexander, Camidge, D. Ross, Lin, Jessica J., Kim, Sang-We, Solomon, Benjamin J., Dziadziuszko, Rafal, Besse, Benjamin, Goto, Koichi, de Langen, Adrianus Johannes, Wolf, Jürgen, Lee, Ki Hyeong, Popat, Sanjay, Springfeld, Christoph, Nagasaka, Misako, Felip, Enriqueta, Yang, Nong, Velcheti, Vamsidhar, Lu, Shun, Kao, Steven, Dooms, Christophe, Krebs, Matthew G., Yao, Wenxiu, Beg, Muhammad Shaalan, Hu, Xiufeng, Moro-Sibilot, Denis, Cheema, Parneet, Stopatschinskaja, Shanna, Mehta, Minal, Trone, Denise, Graber, Armin, Sims, Gregory, Yuan, Yong, Cho, Byoung Chul
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Antineoplastic Agents - therapeutic use Antitumor activity Brain cancer Cancer Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Cell fusion Chemotherapy Critical Care Critical Care General Design Drug dosages Enrollments Genetics Hematology Humans Kinases Laboratories Lung Cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Metastasis Mutation Non-small cell lung carcinoma Oncology Paresthesia Patients Protein-tyrosine kinase Protein-Tyrosine Kinases - antagonists & inhibitors Protein-Tyrosine Kinases - genetics Proto-Oncogene Proteins - antagonists & inhibitors Proto-Oncogene Proteins - genetics Pulmonary Quality of life Questionnaires Small cell lung carcinoma Solid tumors Treatment Outcome Treatments in Oncology Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In this phase 1–2 trial, the TK inhibitor repotrectinib led to an objective response in 79% of patients with ROS1 fusion–positive NSCLC and no previous ROS1 TK inhibitor use. Median progression-free survival was nearly 3 years.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2302299